Effects of collagen IV on cisplatin-induced apoptosis of non-small cell lung cancer cells

Cancer Investigation

Volumn 25, Issue 7, 2007, Pages 542-549

  Su, Chunxia ^a   Su, Bo ^a   Tang, Liang ^a   Zhao, Yinmin ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Apoptosis; Drug resistance; Extracellular matrix; Non small cell lung cancer; PI3 K inhibitor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA1 INTEGRIN; CISPLATIN; COLLAGEN TYPE 4; LAMININ; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SCLEROPROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOCARCINOMA; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; COLLAGEN TYPE IV; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 36248973265     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701513272     Document Type: Article

References (32)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. C.A. Cancer J. Clin. 2005, 55, 74-108
2. Lilenbaum, R.C.; Herndon, J.E. 2nd; List, M.A.; et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J. Clin. Oncol. 2005, 23, 190-6.
3. D'Addario, G.; Pintilie, M.; Leighl, N.B.; Feld, R.; Cerny, T.; Shepherd, F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a metaanalysis of the published literature. J. Clin. Oncol. 2005, 23, 2926-36.
4. Shain, K.H.; Dalton, W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol. Cancer Ther. 2001, 1, 69-78.
5. Dalton, W.S. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist. Updat. 1999, 2, 285-288.
6. Hodkinson, P.S.; Elliott, T.; Wong, W.S.; Rintoul, R.C.; Mackinnon, A.C.; Haslett, C.; et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 2006, 13, 1776-88.
7. DeClerck, Y.A.; Mercurio, A.M.; Stack, M.S.; Chapman, H.A.; Zutter, M.M.; Muschel, R.J.; et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am. J. Pathol. 2004, 164(4), 1131-9.
8. Giancotti, F.G.; Ruoslahti, E. Integrin signaling. Science. 1999, 285, 1028-32.
9. Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Ahtil, A.A.; Dalton, W.S. Cell adhesion mediated drug resistance( CAM-DR):role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999, 93, 1658-1667.
10. Ji-Youn, Han, Hong Sug, Kiim, Sug Hyung, Lee, Won Sang, Park, Jung Young, Lee, Nam Jin, Yoo. Immunohistochemmical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003, 41, 65-70.
11. Hopf, M.; Gohring, W.; Kohfeldt, E.; Yamada, Y.; Timpl, R. Recombinant domain IV of perlecan binds to nidogens, laminin±nidogen complex, fibronectin, fibulin-2 and heparin. Eur. J. Biochem. 1999, 259, 917-25.
12. Hallmann, R.; Horn, N.; Selg, M.; Wendler, O.; Pausch, F.; Sorokin, L.M. Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 2005, 85, 979-1000.
13. Sethi, T.; Rintoul, R.C.; Moore, S.M.; MacKinnon, A.C.; Salter, D.; Choo, C.; et al. Extracellular matrix proteins protect small cell lung cancer cells against: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med, 1999; 5, 662-668.
14. Aoudjit, F.; Vuori, K. Integrin signaling inhibits paclitaexl-induced apoptosis in breast cancer cells. Oncogene 2001, 20, 4995-5004.
15. Kammerer, U.; Kapp, M.; Gassel, A.M.; Richter, T.; Tank, C.; Dietl, J.; et al. A new rapid immunohistochemical staining technique using the EnVision antibody complex. J. Histochem. Cytochem. 2001, 49, 623-30.
16. Nakahara, S.; Miyoshi, E.; Noda, K.; Ihara, S.; Gu, J.; Honke, K. et al. Involvement of oligosaccharide changes in alpha5beta1 integrin in a cisplatin-resistant human squamous cell carcinoma cell line. Mol. Cancer Ther. 2003, 2, 1207-1214.
17. Elliott, T.; Sethi, T. Integrins and extracellular matrix; a novel mechanism of multidrug resistance. Expert. Rev. Anticancer Ther. 2002, 2, 449-459.
18. Dalton, W.S. The tumor microenvironment: focus on myeloma. Cancer Treat Rev. 2003, 29 (Suppl.1), 11-19.
19. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in humancancer. Nat. Rev. Cancer. 2002, 2, 489-501.
20. Hynes, R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992, 69, 11-25.
21. Scott, W.L.; Athena, W.L. Apoptosis in cancer. Carcinogenesis. 2000, 21, 485-495.
22. Diehl, J.A.; Cheng, M.; Roussel, M.F.; Sherr, C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12, 3499-511.
23. Dabholkar, M.; Reed, E. Cisplatin. Cancer Chemother. Biol. Response Modif. 1996, 16, 88-110.
24. Li, X.; Liu, X.; Wang, J.; Wang, Z.; Jiang, W.; Reed, E.; et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res. 2003, 23, 2481-7.
25. Jussila, L.; Alitalo, K. Vascular growth factors and lymphangiogenesis. Physiol. Rev. 2002, 82, 673-700.
26. Elliott, T.; Sethi, T. Integrins and extracellular matrix; a novel mechanism of multidrug resistance. Expert Rev. Anticancer Ther. 2002, 2, 449-459.
27. Andreas, T.; Nicolas, T.S.; Esther, T. MCP-1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282, G145-55.
28. Pinkse, G.G.; Bouwman, W.P.; Jiawan-Lalai, R.; Terpstra, O.T.; Bruijn, J.A.; de Heer, E. Integrin signaling via RGD peptides and anti-beta1 antibodies confers resistance to apoptosis in islets of Langerhans. Diabetes. 2006, 55, 312-7.
29. Tsurutani, J.; West, K.A.; Sayyah, J.; Gills, J.J.; Dennis, P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005, 65, 8423-32.
30. Tsurutani, J.; West, K.A.; Sayyah, J.; Gills, J.J.; Dennis, PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005, 65, 8423-32.
31. Yu, X.R.; Jia, G.R.; Gao, G.D.; Wang, S.H.; Han, Y.; Cao, W. Neuroprotection of insulin against oxidative stress-induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3-kinase/Akt signal pathway. Acta. Biochim. Biophys. Sin. 2006, 38, 241-8.
32. Vanhaesebroeck, B.; Alessi, D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. 2000, 346, Pt 3:561-76.